← Back to Search

Insulin

Human insulin for Pharmacodynamic Response to Insulin

Phase < 1
Waitlist Available
Led By William D. Kirsh, D.O., M.P.H.
Research Sponsored by Transdermal Delivery Solutions Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights

Study Summary

This study is evaluating whether a formula which is applied to the skin may help improve blood sugar levels for individuals with diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Daily Average Serum Glucose Measured in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin
Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject
Secondary outcome measures
OECD Acute Dermal Irritation/Corrosion Score According to to the Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404

Side effects data

From 2021 Phase 4 trial • 452 Patients • NCT04834362
17%
Hypoglycemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Analog Insulin Arm
Human Insulin Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Main ExperimentalExperimental Treatment1 Intervention
Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Insulin human
FDA approved

Find a Location

Who is running the clinical trial?

Langford Research Institute, Inc.Industry Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
Transdermal Delivery Solutions CorpLead Sponsor
4 Previous Clinical Trials
175 Total Patients Enrolled
William D. Kirsh, D.O., M.P.H.Principal InvestigatorLangford Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Transdermal Insulin Response In Healthy Volunteers
2021. "Transdermal Insulin Response In Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04857320.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top